US Patent Issued to H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE on March 3 for "Structure-guided engineering of peptide-based NLRP3 inflammasome inhibitors for myelodysplastic syndromes (MDS)" (Florida Inventors)

ALEXANDRIA, Va., March 3 -- United States Patent no. 12,565,523, issued on March 3, was assigned to H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (Tampa, Fla.).

"Structure-guided engineering of peptide-based NLRP3 inflammasome inhibitors for myelodysplastic syndromes (MDS)" was invented by Alan List (Tampa, Fla.), Haitao Ji (Tampa, Fla.) and Vincent Luca (Tampa, Fla.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are compositions and methods for engineered peptide inhibitors of NLRP3 infiammasome and methods of their use in the treatment of Myelodysplastic Syndromes. In one aspect, disclosed herein are engineered inhibitors of NACHT, LRR and PYD domains-containing protein 3 (NLRP3) infla...